GT Biopharma, Inc.
Price data unavailable
Track GTBP in your trading journalAbout GT Biopharma, Inc.
GT Biopharma, Inc. (GTBP) is a publicly traded US company. GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
The company reports trailing twelve-month revenue of $0 and net loss of $2.83M.
Key metrics include a return on equity of -37.4%, a debt-to-equity ratio of 0.17.
Investors tracking GTBP can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.
Fundamentals
| Revenue (TTM) | $0 |
| Net Income (TTM) | $-2.83M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | -37.37% |
| Debt-to-Equity | 0.17 |
| Dividend per Share | — |
Recent News
- GlobeNewswire Inc.·May 14
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
- GlobeNewswire Inc.·Dec 15
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
- Benzinga·Dec 4
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Want real-time analysis on GTBP?
Track it free in your trading journal. Log trades, tag setups, and review your edge.